Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

NeXstar Pharmaceuticals (AKA: Vestar Research Inc~Vestar Inc)
Profile last edited on: 5/30/21      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1980
First Award
1983
Latest Award
1996
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2860 Wilderness Place
Boulder, CO 80301
   (213) 792-6101
   N/A
   N/A
Location: Single
Congr. District: 02
County: Boulder

Public Profile

Known as Vestar Inc and based in California while the firm was SBIR involved, in the Spring 1995, a reverse merger between two biotech companies, NeXagen (drug discovery) acquired Vestar (liposomal drug delivery)k The two companies merged to form NeXstar Pharmaceuticals focused on cancer and inflammatory and immunological diseases. In 1999. the combined entity was then subsequently sold to Gilead Sciences, itself an SBIR company

Extent of SBIR involvement

User Avatar
Phase I Awards
16
Phase II Awards
4
Conversion Rate
25.00%
Phase I Dollars
$775,062
Phase II Dollars
$1,696,278
Total Awarded
$2,471,340

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : NXTR
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
1996 2 NIH $846,469
Project Title: Liposomal TNF - potential application as cancer therapy
1995 2 NIH $397,865
Project Title: Liposome Encapsulated B-10 For Neutron Capture therapy
1993 1 NIH $50,000
Project Title: Evaluation of Selectively Modified Tumor Necrosis (MTN) Factor
1993 2 Navy $470,688
Project Title: Lyophilization of Liposome Encapsulated Hemoglobin
1991 1 NIH $46,571
Project Title: Liposomal gold compounds - improved antiarthritic therapy

Key People / Management

  Kevin R Bracken

  Richard Callahan

  Eric A Forssen

  Ronald C Gamble

  Richard T Profitt

  Paul G Schmidt

  Joseph A Uliana

Company News

Jul 29 1999
Gilead Acquisition Of NeXstar Completed: New Company Poised to Become a Global Leader in Infectious Disease & Oncology